Vera is now a commercial-stage biotech launching accelerated-approved TRUTAKNA for IgA nephropathy, but its business still hinges on converting that conditional approval into full approval through ORIGIN 3 kidney-function data. The timing of this final analysis and a Q4 2026 supplemental filing was already disclosed, so the surprise is the strength of the evidence rather than the existence of the event.
The confirmatory readout materially strengthens the approval case. The filing says TRUTAKNA met all predefined endpoints, including placebo-adjusted eGFR and composite kidney-progression benefits.
| ORIGIN 3 final result | TRUTAKNA | Placebo / comparison | Filing location |
|---|---|---|---|
| Mean eGFR change at 52 weeks | -0.1 mL/min/1.73m² | -5.7; placebo-adjusted difference 5.6 | (ORIGIN 3 final efficacy analysis) |
| Annualized eGFR slope through 104 weeks | -0.6 mL/min/1.73m²/year | -5.6; placebo-adjusted difference 5.0 | (ORIGIN 3 final efficacy analysis) |
| Composite kidney-progression events | 5% | 18% | (Composite kidney progression endpoint) |
| Risk reduction in composite endpoint | 76% | Hazard ratio 0.24 | (Composite kidney progression endpoint) |
This moves TRUTAKNA from a proteinuria story toward a disease-modifying kidney story. The earlier interim result had already shown a 42% placebo-adjusted reduction in proteinuria, but the final analysis now shows kidney-function preservation through 104 weeks and fewer composite progression events. That is the evidence Vera needed to support its planned sBLA, not merely a repeat of the accelerated-approval surrogate.
Safety looks manageable, but not frictionless. Serious adverse events and discontinuations were numerically lower with TRUTAKNA than placebo, while infections were similar; the trade-off was a higher rate of injection-site reactions and study-drug-related adverse events. The filing describes the overall profile as generally comparable to placebo.
The regulatory path is now clearer, not complete. Vera still needs to submit the supplemental BLA in Q4 2026 and obtain FDA review for full approval; the filing supports that path but does not itself grant the approval. The commercial launch is therefore backed by a substantially stronger clinical package, while the next value-bearing milestone remains regulatory conversion from accelerated to full approval.
Bottom line: This is a meaningful upgrade to Vera’s core story: TRUTAKNA now has confirmatory kidney-function and progression data behind its accelerated approval. The filing turns full approval from a promising possibility into a well-supported next regulatory step, though FDA action is still required.
Read the original 8-K on SEC EDGAR ↗